Molecular characterization of extended-spectrum beta-lactamases produced by clinical isolates of Klebsiella pneumoniae and Escherichia coli from a Korean nationwide survey

Journal of Clinical Microbiology

Volumn 42, Issue 7, 2004, Pages 2902-2906

  Jeong, Seok Hoon ^c,d   Bae, Il Kwon ^c,d   Lee, Jung Hun ^a   Sohn, Seung Ghyu ^b   Kang, Geun Ho ^b   Jeon, Ghil Ja ^b   Kim, Young Ho ^b   Jeong, Byeong Chul ^a   Lee, Sang Hee ^a,b  

^a Myong Ji University   (South Korea)

^b Youngdong University   (South Korea)

^c Kosin University College of Medicine   (South Korea)

^d Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ENZYME; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; CEFOTETAN; CEFOXITIN; CEFTAZIDIME; CMY 1 LIKE BETA LACTAMASE; ENZYME VARIANT; EXTENDED SPECTRUM BETA LACTAMASE; SHV 12 TYPE EXTENDED SPECTRUM BETA LACTAMASE; SHV 2A TYPE EXTENDED SPECTRUM BETA LACTAMASE; SHV TYPE EXTENDED SPECTRUM BETA LACATMASE; TEM 1 TYPE EXTENDED SPECTRUM BETA LACTAMASE; TEM 116 TYPE EXTENDED SPECTRUM BETA LACTAMASE; TEM 19 TYPE EXTENDED SPECTRUM BETA LACTAMASE; TEM 20 TYPE EXTENDED SPECTRUM BETA LACTAMASE; TEM 52 TYPE EXTENDED SPECTRUM BETA LACTAMASE; TEM TYPE EXTENDED SPECTRUM BETA LACTAMASE; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONJUGATION; DNA SEQUENCE; ENZYME ANALYSIS; ENZYME INDUCTION; ESCHERICHIA COLI; ESCHERICHIA COLI SH16; GENOTYPE; HEALTH SURVEY; ISOELECTRIC FOCUSING; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE SV3; KOREA; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR EVOLUTION; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; TRANSCONJUGATION;

BETA-LACTAMASES; ESCHERICHIA COLI; GENOTYPE; HUMANS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; KLEBSIELLA; KLEBSIELLA PNEUMONIAE; NEGIBACTERIA;

EID: 3142701397     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.42.7.2902-2906.2004     Document Type: Article

References (24)

1. CMY-1 gene and its relationship with other beta-lactamase genes. Antimicrob. Agents Chemother. 40:1926-1930.
2. Ben, H. A., G. Fournier, A. Kechird, C. Fendri, R. S. Ben, and A. Phillippon. 1990. Enzymatic resistance to cefotaxime in 56 strains of Klebsiella spp., Escherichia coli and Salmonella spp. at a Tunisian Hospital (1984-1988). Pathol. Biol. (Paris) 38:464-469.
3. Bush, K., G. A. Jacoby, and A. A. Medeiros. 1995. A functional classification scheme for beta-lactamases and its correlation with molecular structure. Antimicrob. Agents Chemother. 39:1211-1233.
4. Chanawong, A., F. H. M'Zali, J. Heritage, A. Lutitanond, and P. M. Hawkey. 2001. SHV-12, SHV-2a and VEB-1 extended-spectrum β-lactamases in Gram-negative bacteria isolated in a university hospital in Thailand. J. Antimicrob. Chemother. 48:839-852.
5. DuBois, S. K., M. S. Marriott, and S. G. B. Amyes. 1995. TEM- and SHV-derived extended-spectrum β-lactamase: relationship between selection, structure and function. J. Antimicrob. Chemother. 35:7-22.
6. Farmer, J. J., III. 1995. Enterobacteriaceae: introduction and identification, p. 438-449. In P. R. Murray, E. J. Baron, M. A. Pfaller, F. C. Tenover, and R. H. Yolken (ed.), Manual of clinical microbiology, 3rd ed. American Society for Microbiology, Washington, D.C.
7. Giakkoupi, P., E. Tzelepi, P. T. Tassios, N. T. Legakis, and L. S. Tzouvelekis. 2000. Determinational effect of the combination of R164S with G238S in TEM-1 beta-lactamase on the extended-spectrum activity conferred by each single mutation. J. Antimicrob. Chemother. 45:101-104.
8. Hall, B. G. 2002. Predicting evolution by in vitro evolution requires determining evolutionary pathways. Antimicrob. Agents Chemother. 46:3035-3038.
9. Hanberger, H., D. Diekema, A. Fluit, R. Jones, M. Struelens, R. Spencer, and M. Wolf. 2001. Surveillance of antibiotic resistance in European ICUs. J. Hosp. Infect. 48:161-176.
10. Jarlier, V., M. H. Nicolas, G. Fournier, and A. Philippon. 1988. Extended broad-spectrum beta-lactamase conferring transferable resistance to newer beta-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibitity patterns. Rev. Infect. Dis. 10:867-878.
11. Kim, J., Y. Kwon, H. Pai, J. W. Kim, and D. T. Cho. 1998. Survey of Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases: prevalence of SHV-12 and SHV-12a in Korea. J. Clin. Microbiol. 36:1446-1449.
12. CMY-11, an AmpC-type plasmid-mediated beta-lactamase gene in a Korean clinical isolate of Escherichia coli. J. Antimicrob. Chemother. 49:269-273.
13. Lee, S. H., J. Y. Kim, S. K. Lee, W. Jin, and K. J. Lee. 2000. Discriminatory detection of extended-spectrum β-lactamases by restriction fragment length dimorphism-polymerase chain reaction. Lett. Appl. Microbiol. 31:307-312.
14. Lee, S. H., J. Y. Kim, S. H. Shin, S. K. Lee, M. M. Choi, I. Y. Lee, Y. B. Kim, J. Y. Cho, W. Jin, and K. J. Lee. 2001. Restriction fragment length dimorphism-PCR method for the detection of extended-spectrum beta-lactamases unrelated to TEM- and SHV-types. FEMS Microbiol. Lett. 200:157-161.
15. Livermore, D. M. 1995. Beta-lactamases in laboratory and clinical resistance. Clin. Microbiol. Rev. 8:557-584.
16. Marchese, A., G. Arlet, G. C. Schito, P. H. Lagrange, and A. Philippon. 1998. Characterization of FOX-3, an AmpC-type plasmid-mediated β-lactamase from an Italian isolate of Klebsiella oxytoca. Antimicrob. Agents Chemother. 42:464-467.
17. National Committee for Clinical Laboratory Standards. 1999. Performance standards for antimicrobial susceptibility testing, 9th ed. Informational supplement. M100-S9. National Committee for Clinical Laboratory Standards, Wayne, Pa.
18. Pai, H., S. Lyu, J. H. Lee, J. Kim, Y. Kwon, J.-W. Kim, and K. W. Choe. 1999. Survey of extended-spectrum beta-lactamases in clinical isolates of Escherichia coli and Klebsiella pneumoniae: prevalence of TEM-52 in Korea. J. Clin. Microbiol. 37:1758-1763.
19. Paterson, D. L., W.-C. Ko, A. Von Gottberg, J. M. Casellas, L. Mulazimoglu, K. P. Klugman, R. A. Bonomo, L. B. Rice, J. G. McCormack, and V. L. Yu. 2001. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum β-lactamases: implications for the clinical microbiology laboratory. J. Clin. Microbiol. 39:2206-2212.
20. Perilli, M., E. Dell'Amico, B. Segatore, M. R. DeMassis, C. Bianchi, F. Luzzaro, G. M. Rossolini, A. Toniolo, G. Nicoletti, and G. Amicosante. 2002. Molecular characterization of extended-spectrum beta-lactamases produced by nosocomial isolates of Enterobateriaceae from an Italian nationwide survey. J. Clin. Microbiol. 40:611-614.
21. Pitout, J. D. D., K. S. Thomson, N. D. Hanson, A. F. Ehrhardt, P. Coudron, and C. C. Sanders. 1998. Plasmid-mediated resistance to expanded-spectrum cephalosporins among Enterobacter aerogenes strains. Antimicrob. Agents Chemother. 42:596-600.
22. Rasheed J. K., C. Jay, B. Metchock, F. Berkowitz, L. Weigel, J. Crellin, C. Steward, B. Hill, A. A. Medeiros, and F. C. Tenover. 1997. Evolution of extended-spectrum beta-lactamase resistance (SHV-8) in a strain of Escherichia coli during multiple episodes of bacteremia. Antimicrob. Agents Chemother. 41:647-653.
23. Sanders, C. C., and W. E. Sanders, Jr. 1992. Beta-lactamase in gram-negative bacteria: global trends and clinical impact. Clin. Infect. Dis. 15:824-839.
24. Stobberingh, E. E., J. A. Hoogkanp-Korstanje, J. Arends, W. H. Goessens, M. R. Visser, and A. G. Buiting. 1999. Occurrence of extended-spectrum beta-lactamases (ESBL) in Dutch hospitals. Infection 27:348-354.